POMC

Biomarker

POMC is involved in appetite and energy regulation. Pathogenic variants are linked to rare genetic obesity disorders and guide targeted therapies.

Approvals

Indications

Therapies

Mapped tests

Where this biomarker is used

Each approval combines this biomarker with a specific indication and therapy. Select a therapy in the tables below to open its FDA-defined testing pathway.

Indication-specific approvals

Approvals where POMC is defined directly in the indication labeling.

Indication	Biomarker criteria	Therapies
Obesity Other · Metabolic	Variants (Pathogenic/Likely Pathogenic) and Variants of Uncertain Significance	IMCIVREE

Tumor-agnostic approvals

Approvals defined at the solid tumor level where POMC is part of the eligibility criteria.

No tumor-agnostic approvals are currently mapped for this biomarker.

Tests that measure this biomarker

These assays report POMC as part of their validated menu. In many cases they are identified in FDA labeling as acceptable companion diagnostics for specific approvals.

Test

POMC/PCSK1/LEPR CDx Panel

Prevention Genetics

Method

NGS

Specimen

Whole blood

Reports POMC as part of its biomarker panel.

1 approvalView test profile →

This view is scoped to POMC. You can also see how it compares with other biomarkers and indications on the Know Your Companions™ map.